Financial Report: Genentech 4Q

Genentech

4Q Revenues: $3.7 billion (+25%)

4Q Earnings: $931 million (+14%)

FY Revenues: $13.4 billion (+14%)

FY Earnings: $3.4 billion (+24%)

Comments: U.S. product sales were $2.5 million in the quarter (+13%) and up 11% to $9.5 million for the year. Avastin sales were $731 million in the quarter (+21%) and $2.7 billion for the year (+17%). Rituxan sales were $677 million in the quarter (+14%) and $2.6 billion for the year (+13%). Herceptin sales were $337 million in the quarter (+3%) and up 7% to $1.4 billion for the year. Lucentis sales were up 20% in the quarter to $236 million, and up 7% for the year to $875 million. R&D expenses were $757 million in the quarter (+22%) and $2.6 billion for the year (+15%).